Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 111, Issue 2, Pages 479-484Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2021.09.038
Keywords
Tacrolimus; Dry eye syndrome; Ocular; Proglycosomes; Nanovesicles
Ask authors/readers for more resources
Topical tacrolimus loaded propylene glycol modified nano-vesicles were found to be more effective than tacrolimus solution in treating experimental dry eye syndrome in rabbits, improving tear production, tear break-up time, ocular surface temperature, and ocular and epithelial damage.
The present work aimed to evaluate the efficacy of topical tacrolimus (0.01%) loaded propylene glycol (PG) modified nano-vesicles (Proglycosomes Nano-vesicles, PNVs) for the treatment of experimental dry eye syndrome (DES) in rabbits. DES was induced by topical application of atropine (1.0%) and benzalkonium chloride (0.1%) aqueous solution. PNVs treatment (PNV group) was compared with tacrolimus solution 0.01% (TAC group) and untreated group and healthy group were used as controls. PNV treated animals showed improved clinical performance with marked increase in tear production and tear break-up time (TBUT). Further, PNVs also subside ocular inflammation as evident from absence of matrix metalloprotenaise-9 and normal ocular surface temperature (32.3 +/- 0.34 degrees C). Additionally, PNVs have positive effect on ocular and epithelial damage observed through low ocular surface staining score and improved globlet cell density. The PNV treatment was found to more effectively compared to TAC solution and most of the parameters were close to those of healthy animals. In conclusion, tacrolimus PNV formulation (0.01%) could be a potential therapy for treatment of dry eye syndrome.(c) 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available